A008930 Stock Overview
Through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Hanmi Science Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩28,650.00 |
| 52 Week High | ₩56,200.00 |
| 52 Week Low | ₩25,750.00 |
| Beta | 0.93 |
| 1 Month Change | -12.92% |
| 3 Month Change | -15.24% |
| 1 Year Change | -25.20% |
| 3 Year Change | -45.71% |
| 5 Year Change | -17.38% |
| Change since IPO | 6,101.95% |
Recent News & Updates
Recent updates
Is Hanmi Science (KRX:008930) Using Too Much Debt?
Nov 14
Hanmi Science Co., Ltd. (KRX:008930) Looks Just Right With A 27% Price Jump
Oct 27Returns On Capital Are Showing Encouraging Signs At Hanmi Science (KRX:008930)
Aug 30Here's Why Hanmi Science (KRX:008930) Can Manage Its Debt Responsibly
Aug 13Hanmi Science Co., Ltd. (KRX:008930) Not Flying Under The Radar
Jul 22Is Hanmi Science (KRX:008930) Using Too Much Debt?
Apr 29Hanmi Science Co., Ltd.'s (KRX:008930) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Jan 31
We Think Hanmi Science (KRX:008930) Can Stay On Top Of Its Debt
Jan 05Shareholders Are Thrilled That The Hanmi Science (KRX:008930) Share Price Increased 100%
Dec 06Shareholder Returns
| A008930 | KR Healthcare | KR Market | |
|---|---|---|---|
| 7D | -5.6% | -4.8% | -3.7% |
| 1Y | -25.2% | -22.0% | -10.4% |
Return vs Industry: A008930 underperformed the KR Healthcare industry which returned -22% over the past year.
Return vs Market: A008930 underperformed the KR Market which returned -10.4% over the past year.
Price Volatility
| A008930 volatility | |
|---|---|
| A008930 Average Weekly Movement | 14.1% |
| Healthcare Industry Average Movement | 9.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A008930's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A008930's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 444 | Jong-Hoon Lim | www.hanmiscience.co.kr |
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult’s bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment.
Hanmi Science Co., Ltd. Fundamentals Summary
| A008930 fundamental statistics | |
|---|---|
| Market cap | ₩1.94t |
| Earnings (TTM) | ₩104.96b |
| Revenue (TTM) | ₩1.28t |
18.5x
P/E Ratio1.5x
P/S RatioIs A008930 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A008930 income statement (TTM) | |
|---|---|
| Revenue | ₩1.28t |
| Cost of Revenue | ₩986.45b |
| Gross Profit | ₩297.20b |
| Other Expenses | ₩192.24b |
| Earnings | ₩104.96b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.55k |
| Gross Margin | 23.15% |
| Net Profit Margin | 8.18% |
| Debt/Equity Ratio | 25.3% |
How did A008930 perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield13%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 01:49 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hanmi Science Co., Ltd. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Young-Ah Han | BofA Global Research |
| Jeehye Song | Goldman Sachs |
| Jin Kyun Lim | IBK Securities Co. Ltd. |